Study of DWP712 for frown lines
Treatments studied
Part of Skin clinical trials.
This study tests an injection called DWP712 to see how well it smooths moderate to severe frown lines between the eyebrows (glabellar lines). If you have noticeable frown lines that bother you, this treatment might be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have moderate to severe frown lines (a score of 2 or higher on a facial wrinkle scale) when you frown hard.
- Your frown lines should be able to be smoothed out by pulling the skin apart, according to the study doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an injection called HU-045 to reduce moderate to severe frown lines. It may help adults who want to soften those vertical lines between the eyebrows.
This study tests two different injection treatments for moderate to severe frown lines between the eyebrows. It aims to find the best way to use these treatments to improve your appearance.
This study tests a new botulinum toxin injection (similar to Botox) to reduce frown lines between the eyebrows. It aims to see if it's safe and effective for Japanese adults aged 18 to 64.
This study tests a new botulinum toxin injection (similar to Botox) to see how well it smooths moderate to severe frown lines between the eyebrows. The treatment is given as a single injection and may help soften those lines for several months.
This trial tests an injectable treatment for moderate to severe forehead lines and frown lines in adults. It aims to see if the injections can safely reduce the appearance of these lines.
This study tests a new medication (IPN10200) to safely reduce moderate to severe frown lines between the eyebrows in adults. It may help if you are bothered by these lines and are looking for a non-surgical option.
Hear when a new Glabellar Lines trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.